[HTML][HTML] Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review of disease information and future perspectives
Amyotrophic lateral sclerosis (ALS) is a rare deadly progressive neurological disease that
primarily affects the upper and lower motor neurons with an annual incidence rate of 0.6 to …
primarily affects the upper and lower motor neurons with an annual incidence rate of 0.6 to …
Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis
TF Gendron, LM Daughrity, MG Heckman… - Annals of …, 2017 - Wiley Online Library
As potential treatments for C9ORF72‐associated amyotrophic lateral sclerosis (c9ALS)
approach clinical trials, the identification of prognostic biomarkers for c9ALS becomes a …
approach clinical trials, the identification of prognostic biomarkers for c9ALS becomes a …
Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
A Brodovitch, J Boucraut, E Delmont, A Parlanti… - Scientific reports, 2021 - nature.com
This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis
(ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light …
(ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light …
Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
Since amyotrophic lateral sclerosis cases exhibit significant heterogeneity, we aim to
investigate the association of lipid composition of plasma and CSF with amyotrophic lateral …
investigate the association of lipid composition of plasma and CSF with amyotrophic lateral …
ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia
Background Amyotrophic lateral sclerosis (ALS) is a debilitating disease with few treatment
options. Progress towards new therapies requires validated disease biomarkers, but there is …
options. Progress towards new therapies requires validated disease biomarkers, but there is …
Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown cause.
Absence of specific targets and biomarkers compromise the development of new therapeutic …
Absence of specific targets and biomarkers compromise the development of new therapeutic …
Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
Abstract Introduction/Aims We tested safety, tolerability, and target engagement of
tocilizumab in amyotrophic lateral sclerosis (ALS) patients. Methods Twenty‐two …
tocilizumab in amyotrophic lateral sclerosis (ALS) patients. Methods Twenty‐two …
Discovery of biomarkers for amyotrophic lateral sclerosis from human cerebrospinal fluid using mass-spectrometry-based proteomics
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
characterized by the loss of upper and lower motor neurons, which eventually may lead to …
characterized by the loss of upper and lower motor neurons, which eventually may lead to …
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
K Imamura, Y Izumi, M Nagai, K Nishiyama… - …, 2022 - thelancet.com
Background Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
disease caused by the loss of motor neurons, and development of effective medicines is …
disease caused by the loss of motor neurons, and development of effective medicines is …
Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis
C Carlomagno, PI Banfi, A Gualerzi, S Picciolini… - Scientific Reports, 2020 - nature.com
Abstract Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease leading to
progressive and irreversible muscle atrophy. The diagnosis of ALS is time-consuming and …
progressive and irreversible muscle atrophy. The diagnosis of ALS is time-consuming and …